Janux Therapeutics JANX
Janux Therapeutics FY 2021: net loss $32.7M; diluted EPS −$1.39
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-22-004171
- Document
- 10-K
- Exhibit 4.4
- Warrants or notes
- Exhibit 10.14
- Material contract
- Exhibit 10.15
- Material contract
- Exhibit 10.17
- Material contract
Key figures from this report
These are the numbers Janux Therapeutics reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$32.7MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS−$1.39No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$35.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$17.0MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Spyre Therapeutics SYRE public float $1.1B, Jun 30, 2025
- Schrodinger SDGR public float $1.1B, Jun 30, 2025
- Mannkind MNKD public float $1.1B, Jun 30, 2025
- Novavax NVAX public float $1.0B, Jun 30, 2025
- Harrow HROW public float $1.0B, Jun 30, 2025